Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Epoprostenol
Drug ID BADD_D00788
Description A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Indications and Usage For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Marketing Status approved
ATC Code B01AC09
DrugBank ID DB01240
KEGG ID D00106
MeSH ID D011464
PubChem ID 5282411
TTD Drug ID D0V0IX
NDC Product Code 66215-402; 62756-060; 66215-403; 62287-123; 62756-059
UNII DCR9Z582X0
Synonyms Epoprostenol | Epoprostanol | Prostaglandin I2 | Prostacyclin | Prostaglandin I(2) | Veletri | Epoprostenol Sodium | Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer | Flolan
Chemical Information
Molecular Formula C20H32O5
CAS Registry Number 35121-78-9
SMILES CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thirst08.01.09.021; 14.03.02.007--Not Available
Throat irritation22.12.03.029; 07.05.05.0370.000222%Not Available
Thrombocytopenia01.08.01.0020.000798%Not Available
Thrombosis24.01.01.0060.000452%Not Available
Toothache07.09.06.0010.000082%
Tremor17.01.06.002--
Umbilical hernia07.16.03.0010.000082%Not Available
Unresponsive to stimuli17.02.05.0310.000329%Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.000222%
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Venous thrombosis24.01.01.0080.000123%Not Available
Ventricular arrhythmia02.03.04.0060.000082%
Vomiting07.01.07.0030.004556%
Weight decreased13.15.01.005--
Wheezing22.03.01.0090.000304%
Mental status changes19.07.01.0010.000699%Not Available
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.0080.000288%Not Available
Seasonal allergy10.01.04.001; 22.04.04.008; 06.04.01.0130.000280%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.000633%Not Available
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.0060.000164%
Application site inflammation12.07.01.024; 08.02.01.0240.000181%Not Available
Autoimmune thyroiditis10.04.08.006; 05.02.04.0020.000123%Not Available
General physical health deterioration08.01.03.0180.000757%Not Available
Shock haemorrhagic24.06.02.014; 14.05.05.0030.000082%Not Available
Muscle tightness15.05.03.0070.000082%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000082%
Lower gastrointestinal haemorrhage24.07.02.030; 07.12.03.0110.000082%
Cardiopulmonary failure02.05.01.004; 22.02.06.0040.000164%Not Available
Catheter site haemorrhage24.07.01.003; 12.07.02.002; 08.02.02.0020.001489%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 14 Pages